The Baveno Cooperation: an EASL Consortium (@bavenocoop) 's Twitter Profile
The Baveno Cooperation: an EASL Consortium

@bavenocoop

The official account of the Baveno Cooperation

ID: 1413187741311983623

calendar_today08-07-2021 17:27:18

494 Tweet

2,2K Takipçi

168 Takip Edilen

Asociación Española para el Estudio del Hígado (@aeehliver) 's Twitter Profile Photo

‼️Las sociedades científicas, entre ellas la #AEEH, nos unimos, a iniciativa de Sociedad Española de Medicina Interna (SEMI) semFYC y SESPAS, en una campaña para prevenir y reducir los impactos negativos del alcohol en la salud. ❌Conoce las medidas que proponemos para reducir la demanda y regular la

‼️Las sociedades científicas, entre ellas la #AEEH, nos unimos, a iniciativa de <a href="/Sociedad_SEMI/">Sociedad Española de Medicina Interna (SEMI)</a> <a href="/semfyc/">semFYC</a> y <a href="/sespas/">SESPAS</a>, en una campaña para prevenir y reducir los impactos negativos del alcohol en la salud.
❌Conoce las medidas que proponemos para reducir la demanda y regular la
EASL Education (@easledu) 's Twitter Profile Photo

What defines a good TIPS candidate? How do we assess risk and optimise outcomes? 🔴 Join experts in 1 hour to explore strategies in TIPS management! 🔗 Register here: easl-eu.zoom.us/webinar/regist… EASLnews Virginia Manhal Izzy Sven Francque The Baveno Cooperation: an EASL Consortium Dr.Bornie

George Ioannou (@gnioannou) 's Twitter Profile Photo

1⃣Is MASLD associated with non-liver related mortality? 2⃣Is it *independently* associated with non-liver related mortality after adjusting for cardiometabolic factors? 3⃣Does MASLD *CAUSE* excess non-liver-related mortality? See Journal of Hepatology : authors.elsevier.com/a/1l6X6cOnAYPVk

1⃣Is MASLD associated with non-liver related mortality?
2⃣Is it *independently* associated with non-liver related mortality after adjusting for cardiometabolic factors?
3⃣Does MASLD *CAUSE* excess non-liver-related mortality?

See <a href="/JHepatology/">Journal of Hepatology</a> :

authors.elsevier.com/a/1l6X6cOnAYPVk
EASLnews (@easlnews) 's Twitter Profile Photo

Register for this #EASLDeepDive to learn all about the pathophysiology and clinical progression of #MASLD. Key topics include: 🔑Unmet Clinical Needs 🔑Valuable clinical endpoints 🔑Emerging therapies to improve patient care 🔗 easl-eu.zoom.us/webinar/regist… Gyorgy Baffy Sven Francque

Register for this #EASLDeepDive to learn all about the pathophysiology and clinical progression of #MASLD. 

Key topics include: 
🔑Unmet Clinical Needs
🔑Valuable clinical endpoints 
🔑Emerging therapies to improve patient care

🔗 easl-eu.zoom.us/webinar/regist…

<a href="/gbaffy/">Gyorgy Baffy</a> <a href="/FrancqueSven/">Sven Francque</a>
Thomas Reiberger (@reibergerthomas) 's Twitter Profile Photo

⚠️ #Hepatitis C Elimination EASLnews World Health Organization (WHO) The Lancet Gastroenterology & Hepatology 😑 not all countries have national HCV action plans ☹️ 36% have (partial) restrictions on curative #HCV treatments 😑 30% met HCV #WHO diagnosis coverage target of 60% ☹️ only 15% met HCV #WHO treatment target

⚠️ #Hepatitis C Elimination
<a href="/EASLnews/">EASLnews</a> <a href="/WHO/">World Health Organization (WHO)</a> 
<a href="/LancetGastroHep/">The Lancet Gastroenterology & Hepatology</a> 

😑 not all countries have national HCV action plans
☹️ 36% have (partial) restrictions on curative #HCV treatments
😑 30% met HCV #WHO diagnosis coverage target of 60%
☹️ only 15% met HCV #WHO treatment target
Thomas Reiberger (@reibergerthomas) 's Twitter Profile Photo

⚠️ #Hepatitis B Elimination EASLnews World Health Organization (WHO) The Lancet Gastroenterology & Hepatology 😑 73% met #WHO criterion of ≤0.5% HBsAg prevalence 😑 67% have universal #HBV birth vaccinations ☹️ Suboptimal #WHO diagnosis coverage target of 60% 😱 no country met #HBV treatment target

⚠️ #Hepatitis B Elimination
<a href="/EASLnews/">EASLnews</a> <a href="/WHO/">World Health Organization (WHO)</a> 
<a href="/LancetGastroHep/">The Lancet Gastroenterology & Hepatology</a> 

😑 73% met #WHO criterion of ≤0.5% HBsAg prevalence
😑 67% have universal #HBV birth vaccinations
☹️ Suboptimal #WHO diagnosis coverage target of 60%
😱 no country met #HBV treatment target
EndoCollab™ | GI Endoscopy Community (@endocollabcom) 's Twitter Profile Photo

Vasomics of the Liver Review on the importance of the vascular system of the liver in disease occurrence, progression and response to treatment Reference/source: https://gut.bmj .com/content/74/6/1008

Vasomics of the Liver

Review on the importance of the vascular system of the liver in disease occurrence, progression and response to treatment

Reference/source: https://gut.bmj .com/content/74/6/1008
EASLnews (@easlnews) 's Twitter Profile Photo

EASL has released new CPGs on abdominal extrahepatic surgery in patients with cirrhosis and advanced chronic liver disease at #EASLCongress—a critical step in improving surgical outcomes for this high-risk population. 🏥🩺 🔍 Why it matters: As non-hepatic abdominal surgeries

EASL has released new CPGs on abdominal extrahepatic surgery in patients with cirrhosis and advanced chronic liver disease at #EASLCongress—a critical step in improving surgical outcomes for this high-risk population. 🏥🩺

🔍 Why it matters:
As non-hepatic abdominal surgeries
Salvatore Piano (@salvatore_piano) 's Twitter Profile Photo

📣New data on cirrhosis recompensation in Journal of Hepatology ✅Only 7% meets strict Baveno VII criteria ✅Expanded criteria capture ~38% with similar low mortality risk Recompensation: ⬇️systemic inflammation🔥 👍 improved hemodynamic ⬆️improved survival doi.org/10.1016/j.jhep…

📣New data on cirrhosis recompensation in <a href="/JHepatology/">Journal of Hepatology</a> 

✅Only 7% meets strict Baveno VII criteria
✅Expanded criteria capture ~38% with similar low mortality risk

Recompensation:
⬇️systemic inflammation🔥
👍 improved hemodynamic
⬆️improved survival

doi.org/10.1016/j.jhep…
Salvatore Piano (@salvatore_piano) 's Twitter Profile Photo

Who has lower probability of recompensation? 1️⃣⬆️ MELD 2️⃣🤕further decompensation before etiological cure 🤔 Point of non return? 3️⃣⬆️ BMI 🤔 underlying MASLD? More data are coming AASLDThomas Reiberger The Baveno Cooperation: an EASL Consortium

Gut Journal (@gut_bmj) 's Twitter Profile Photo

#GUTImage from the #RecentAdvancesInClinicalPractice paper by Wang et al entitled "Vasomics of the liver" via bit.ly/3Fkske5 #Vasomics #CLD

#GUTImage from the #RecentAdvancesInClinicalPractice paper by Wang et al entitled

"Vasomics of the liver" via bit.ly/3Fkske5

#Vasomics #CLD